Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PPM1B | O75688 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.34 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.34 |
| ▸ | GLB1 | P16278 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2201847 | 1.00 | DPP4 (0.37) | DPP4DPP8DPP9KDM4ECYP1A2 | |
| SCHEMBL3316703 | 1.00 | DPP4 (0.37) | DPP4DPP8DPP9KDM4ECYP1A2 | |
| SCHEMBL1567974 | 1.00 | DPP4 (0.37) | DPP4DPP8DPP9KDM4ECYP1A2 | |
| SCHEMBL9684605 | 1.00 | DPP4 (0.37) | DPP4DPP8DPP9KDM4ECYP1A2 | |
| SCHEMBL1470851 | 1.00 | DPP4 (0.37) | DPP4DPP8DPP9KDM4ECYP1A2 | |
| SCHEMBL2389792 | 1.00 | DPP4 (0.37) | DPP4DPP8DPP9KDM4ECYP1A2 | |
| Hydrochloric Acid SCHEMBL7312757 | 0.98 | KDM4E (0.38) | DPP4DPP8DPP9KDM4ECYP1A2 | |
| Hydrochloric Acid SCHEMBL2705454 | 0.98 | KDM4E (0.38) | DPP4DPP8DPP9KDM4ECYP1A2 | |
| Hydrochloric Acid SCHEMBL132277 | 0.98 | KDM4E (0.38) | DPP4DPP8DPP9KDM4ECYP1A2 | |
| Hydrochloric Acid SCHEMBL7306465 | 0.98 | KDM4E (0.38) | DPP4DPP8DPP9KDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176923-A1 | Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors | SALAMA ZOSER B | 2008-07-24 | — | — | US | claimed |
| US-20250295157-A1 | METHODS FOR THE IMPROVEMENT AND MAINTENANCE OF WEIGHT LOSS | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2025-09-25 | — | — | US | disclosed |
| US-12349713-B2 | Methods for the improvement and maintenance of weight loss | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2025-07-08 | — | — | US | disclosed |
| WO-2023183616-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | SENDA BIOSCIENCES, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-4099849-A1 | COMPOSITIONS AND METHODS FOR THE IMPROVEMENT AND MAINTENANCE OF GLUCOSE METABOLISM IN CHILDHOOD AND ADOLESCENCE | Société des Produits Nestlé S.A. (CH) | 2022-12-14 | — | — | EP | disclosed |
| US-20220369685-A1 | COMPOSITIONS AND METHODS FOR THE IMPROVEMENT AND MAINTENANCE OF GLUCOSE METABOLISM IN CHILDHOOD AND ADOLESCENCE | NESTLE SA (CH) | 2022-11-24 | — | — | US | disclosed |
| US-20220338521-A1 | COMPOSITIONS AND METHODS FOR THE IMPROVEMENT AND MAINTENANCE OF WEIGHT LOSS | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2022-10-27 | — | — | US | disclosed |
| CN-114980753-A | Compositions and methods for improving and maintaining glucose metabolism in children and adolescents | 雀巢产品有限公司 | 2022-08-30 | — | — | CN | disclosed |
| EP-4033922-A1 | COMPOSITIONS AND METHODS FOR THE IMPROVEMENT AND MAINTENANCE OF WEIGHT LOSS | Société des Produits Nestlé S.A. (CH) | 2022-08-03 | — | — | EP | disclosed |
| CN-114423304-A | Compositions and methods for improvement and maintenance of weight loss | 雀巢产品有限公司 | 2022-04-29 | — | — | CN | disclosed |
| US-10328051-B2 | Proline or proline derivatives for the treatment of dementia | SALAMA ZOSER B (DE) | 2019-06-25 | — | — | US | disclosed |
| US-20170239215-A1 | PROLINE OR PROLINE DERIVATIVES FOR THE TREATMENT OF DEMENTIA | SALAMA ZOSER B (DE) | 2017-08-24 | — | — | US | disclosed |
| US-20080176923-A1 | Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors | SALAMA ZOSER B | 2008-07-24 | — | — | US | disclosed |
| EP-1711462-A1 | PROLINE DERIVATIVES USED AS PHARMACEUTICAL ACTIVE INGREDIENTS FOR THE TREATMENT OF TUMOURS | Salama, Zoser B. nat.rer.Dr. (DE) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005058816-A1 | PROLINE DERIVATIVES USED AS PHARMACEUTICAL ACTIVE INGREDIENTS FOR THE TREATMENT OF TUMOURS | SALAMA ZOSER B (DE) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10328051-B2 | Proline or proline derivatives for the treatment of dementia | PSEN2, PSEN1, PRNP | DPP4 120/4885DPP8 265/4885DPP9 336/4885 |
| US-20170239215-A1 | PROLINE OR PROLINE DERIVATIVES FOR THE TREATMENT OF DEMENTIA | PSEN2, PSEN1, PRNP | DPP4 120/4885DPP8 265/4885DPP9 336/4885 |
| US-20080176923-A1 | Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors | PREP, PRAP1, VHL | DPP4 270/4885DPP8 395/4885DPP9 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.